Final Analysis of a Trial of M72/AS01

Simple item page
dc.contributor.affiliationFrom the International AIDS Vaccine Initiative (IAVI) (D.R.T.), the South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology (M.H., T.J.S., M.T.), and the Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (F.T., R.J.W.), University of Cape Town, TASK Applied Science (E.V.B., A.D.), and Stellenbosch University (A.D.), Cape Town, the Be Part Yoluntu Centre, Paarl (E.H.), the Aurum Institute, Klerksdorp Research Centre, Klerksdorp (J.C.I.), the Aurum Institute, Tembisa Research Centre, Tembisa (J.C.I.), Setshaba Research Centre, Pretoria (M. Malahleha), and the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South African Medical Research Council Collaborating Centre for HIV/AIDS and TB, and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, University of the Witwatersrand, Johannesburg (N.M.) - all in South Africa; GlaxoSmithKline, Wavre, and GlaxoSmithKline, Rixensart - both in Belgium (O.V.D.M., B.S., E.J.A., A.B., M.-A.D., P.G., D.M.V., T.G.P., F.R.); the IAVI, New York (A.M.G., T.G.E., M.L.); Zambart, University of Zambia (H.M.A.), and the Centre for Infectious Disease Research in Zambia (M. Muyoyeta) - both in Lusaka; the London School of Hygiene and Tropical Medicine (H.M.A.) and Francis Crick Institute and the Department of Medicine, Imperial College London (R.J.W.) - all in London; Johns Hopkins University Center for Tuberculosis Research, Baltimore (N.M.); the Kenya Medical Research Institute Centre for Respiratory Diseases Research, Nairobi (V.N.); and the Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland (F.T.).
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorTait DR
dc.contributor.authorHatherill M
dc.contributor.authorVan Der Meeren O
dc.contributor.authorGinsberg AM
dc.contributor.authorVan Brakel E
dc.contributor.authorSalaun B
dc.contributor.authorScriba TJ
dc.contributor.authorAkite EJ
dc.contributor.authorAyles HM
dc.contributor.authorBollaerts A
dc.contributor.authorDemoitié MA
dc.contributor.authorDiacon A
dc.contributor.authorEvans TG
dc.contributor.authorGillard P
dc.contributor.authorHellström E
dc.contributor.authorInnes JC
dc.contributor.authorLempicki M
dc.contributor.authorMalahleha M
dc.contributor.authorMartinson N
dc.contributor.authorMesia Vela D
dc.contributor.authorMuyoyeta M
dc.contributor.authorNduba V
dc.contributor.authorPascal TG
dc.contributor.authorTameris M
dc.contributor.authorThienemann F
dc.contributor.authorWilkinson RJ
dc.contributor.authorRoman F
dc.date.accessioned2025-05-23T11:41:16Z
dc.date.issued2019-Dec-19
dc.description.abstractBACKGROUND: Results of an earlier analysis of a trial of the M72/AS01 METHODS: From August 2014 through November 2015, we enrolled adults 18 to 50 years of age with RESULTS: A total of 3575 participants underwent randomization, of whom 3573 received at least one dose of M72/AS01 CONCLUSIONS: Among adults infected with
dc.identifier.doi10.1056/NEJMoa1909953
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10442
dc.sourceThe New England journal of medicine
dc.titleFinal Analysis of a Trial of M72/AS01

Files

Collections

Published